Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03179943
Title Overcoming Chechkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fox Chase Cancer Center

transitional cell carcinoma


Atezolizumab + Guadecitabine

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.